Tirzepatide (Mounjaro / Zepbound)

Tirzepatide is a 39-amino-acid synthetic peptide that functions as a dual agonist at two incretin hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Developed by Eli Lilly under the brand names Mounjaro (type 2 diabetes indication) and Zepbound (obesity/weight management indication), tirzepatide represents a mechanistic evolution beyond earlier GLP-1 monotherapy agents such as semaglutide. It is classified as a 'twincretin' due to its simultaneous engagement of both incretin pathways. This profile is published for educational purposes only and does not constitute medical advice or a recommendation for use.

Tirzepatide's mechanism of action involves co-activation of GIP and GLP-1 receptors, which are expressed in the pancreas, central nervous system, adipose tissue, and gastrointestinal tract. Research suggests GLP-1R activation drives glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via hypothalamic signaling. GIPR activation is believed to complement these effects through enhanced insulin sensitivity in adipose tissue and potentially favorable effects on energy expenditure — though the precise contribution of GIPR agonism to the clinical weight loss signal remains an active area of investigation. The molecule is acylated with a C20 fatty diacid moiety, conferring a half-life of approximately 5 days (around 116–120 hours) and enabling once-weekly subcutaneous dosing.

The evidence base for tirzepatide is unusually robust for any compound reviewed on this platform. The SURPASS clinical program comprised multiple Phase III randomized controlled trials enrolling thousands of participants with type 2 diabetes. SURPASS-2 (n=1,879, 2021) demonstrated statistically significant HbA1c reductions of up to 2.37 percentage points and mean weight loss of up to 12.4 kg versus semaglutide 1mg. The SURMOUNT-1 trial (n=2,539, 2022, published in NEJM) — specifically designed around obesity endpoints — reported mean weight reductions of 15.0% at 5mg, 19.5% at 10mg, and 20.9% at 15mg versus 3.1% for placebo over 72 weeks. A SURMOUNT-2 trial in participants with obesity and type 2 diabetes reported similar findings. These are human Phase III RCTs with large sample sizes; this level of evidence is exceptional relative to most peptides in the research-chemical space. Anecdotally, user forums report results broadly consistent with trial data, with many noting faster early response than semaglutide at equivalent initiation doses — though self-reported data carry all the standard confounds.

Dosing in the clinical trials followed an escalation protocol starting at 2.5mg subcutaneously once weekly for 4 weeks, titrated in 2.5mg increments at 4-week intervals to maintenance doses of 5mg, 10mg, or 15mg once weekly. The 15mg dose was the highest evaluated and showed the greatest efficacy signal. These ranges are reported strictly in research and clinical contexts — they are not a dosing recommendation, and tirzepatide should only be used under physician supervision following a valid prescription. The FDA-approved titration schedule exists specifically to manage gastrointestinal tolerability during dose escalation.

Tirzepatide holds FDA approval (US), EMA approval (EU), MHRA approval (UK), and TGA approval (Australia) for specific indications. In the United States, Mounjaro is approved for glycemic control in type 2 diabetes (June 2022) and Zepbound is approved for chronic weight management in adults with a BMI ≥30 or ≥27 with at least one weight-related comorbidity (November 2023). Legitimate access pathways in the US include licensed endocrinologists, primary care physicians, and telehealth platforms such as Ro, Hims/Hers, and Mochi Health that operate within FDA-compliant prescribing frameworks. Compounded tirzepatide from 503A/503B pharmacies has been available during documented shortage periods under FDA enforcement discretion, though this status is subject to change and carries additional sourcing considerations. Research-chemical sourcing of tirzepatide is strongly discouraged: unlike peptides without approved pharmaceutical equivalents, obtaining tirzepatide outside the prescription pathway introduces risks around purity, concentration accuracy, and legal exposure with no offsetting benefit given the legitimate access route available.